Thrivent Financial for Lutherans Has $144.77 Million Position in Labcorp Holdings Inc. $LH

Posted by Brian Himes on May 15th, 2026

Thrivent Financial for Lutherans increased its holdings in Labcorp Holdings Inc. (NYSE:LH – Free Report) by 2.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 577,027 shares of the medical research company’s stock after purchasing an additional 14,021 shares during the period. Thrivent Financial for Lutherans’ holdings in Labcorp were worth $144,765,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in Labcorp by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 9,850,631 shares of the medical research company’s stock worth $2,471,326,000 after purchasing an additional 37,197 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in Labcorp by 20.0% in the third quarter. Victory Capital Management Inc. now owns 2,637,350 shares of the medical research company’s stock worth $756,878,000 after purchasing an additional 440,224 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Labcorp by 10.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,204,276 shares of the medical research company’s stock worth $554,728,000 after purchasing an additional 207,962 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Labcorp by 15.9% in the third quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock worth $604,488,000 after purchasing an additional 289,029 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in Labcorp by 4.0% in the third quarter. Bank of America Corp DE now owns 726,090 shares of the medical research company’s stock worth $208,431,000 after purchasing an additional 27,879 shares in the last quarter. 95.94% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Adam H. Schechter sold 8,705 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $279.96, for a total transaction of $2,437,051.80. Following the transaction, the chief executive officer owned 80,773 shares in the company, valued at approximately $22,613,209.08. The trade was a 9.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Brian J. Caveney sold 1,500 shares of the business’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total transaction of $429,465.00. Following the transaction, the executive vice president owned 30,107 shares in the company, valued at approximately $8,619,935.17. The trade was a 4.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 16,656 shares of company stock valued at $4,524,961 in the last quarter. Insiders own 0.84% of the company’s stock.

Labcorp Stock Down 0.2%

Labcorp stock opened at $253.87 on Friday. The firm has a market cap of $20.82 billion, a price-to-earnings ratio of 22.49, a P/E/G ratio of 1.78 and a beta of 0.91. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.73 and a quick ratio of 1.54. Labcorp Holdings Inc. has a fifty-two week low of $239.67 and a fifty-two week high of $293.72. The firm has a fifty day moving average price of $265.94 and a two-hundred day moving average price of $265.73.

Labcorp (NYSE:LH – Get Free Report) last released its earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $4.09 by $0.16. The firm had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The business’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, analysts forecast that Labcorp Holdings Inc. will post 17.99 earnings per share for the current year.

Labcorp Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Friday, May 29th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, May 29th. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. Labcorp’s payout ratio is currently 25.51%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on LH shares. Evercore reiterated an “outperform” rating and issued a $300.00 price objective on shares of Labcorp in a report on Wednesday, April 8th. Robert W. Baird set a $334.00 price objective on shares of Labcorp in a report on Friday, May 1st. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Morgan Stanley reiterated an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. Finally, Piper Sandler upped their price objective on shares of Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a report on Tuesday, February 24th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Labcorp has an average rating of “Moderate Buy” and a consensus price target of $308.00.

Get Our Latest Report on Labcorp

Labcorp Profile

(Free Report)

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.